Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 478

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 478
---
        2028

        32,279

        2029

        25,796

        Thereafter

        229,353

        Total minimum lease payments

        382,272

        Less: imputed interest and tenant incentive reimbursable by lessors

        (176,526
        )

        Total operating lease liabilities
         
        $
        205,746

        Included in the consolidated balance sheet:

        Current portion of lease liabilities within other current liabilities
         
        $
        13,273

        Lease liabilities, non-current

        192,473

        Total operating lease liabilities
         
        $
        205,746

20. EARNINGS (LOSS) PER SHAREBasic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the treasury stock method for stock awards and the if-converted method for convertible debt by dividing net income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding. Given that the Company recorded a net loss for the years ended December 31, 2023 and 2022, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.The following table sets forth the computation of basic and diluted earnings (loss) per common share: 

        For the Year Ended December 31,

        2024

        2023

        2022

        (in thousands, except per share amounts)

        Numerator:

        Net income (loss) – basic
         
        $
        235,239

        $
        (535,977
        )
         
        $
        (703,488
        )

        Add: interest expense, net of tax, on the Company's     convertible debt

        17,000

        —

        —

        Net income (loss) – diluted
         
        $
        252,239

        $
        (535,977
        )
         
        $
        (703,488
        )

        Denominator:

        Weighted-average common shares outstanding, basic

        95,075

        92,398

        87,559

        Effect of dilutive securities:

        Common stock issuable under the Company's     equity